insights_auto
Why is CLLS down 11.01%?
Dive Deeperchevron_right
CLLS:NASDAQ
Cellectis SA
$0.93
arrow_downward
-11.01%(-0.11) 1D
Oct 19, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CLLS...
Open
$1.04
High
$1.04
Low
$0.88
Mkt. cap
74.48M
Avg. vol.
166.82K
Volume
224.84K
52-wk high
$5.45
52-wk low
$0.88
EPS
-$0.65
Beta
3.00
Shares outstanding
72.09M
No. of employees
227
Open
$1.04
High
$1.04
Low
$0.88
Mkt. cap
74.48M
Avg. vol.
166.82K
Volume
224.84K
52-wk high
$5.45
52-wk low
$0.88
EPS
-$0.65
Beta
3.00
Shares outstanding
72.09M
No. of employees
227
News stories
From web sources and news partners
Stocktwits
·
1 hour ago
Dow, S&P 500, Nasdaq Edge Higher Amid Tech Rebound As Q3 Earnings Season Forges Ahead: DJT, AMZN, CBRS, CRWV Stocks In Focus
Investing.com
·
8 hours ago
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.07%
BigGo Finance
·
7 hours ago
Nasdaq Rises 1.1% as Chip Stocks Rebound After Nine-Session Slide; AI Names Draw Buyers, Dow Edges Lower
ETF Database
·
5 hours ago
World Markets Watchlist: October 19, 2026
Profile
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina. Wikipedia
About Cellectis SA